Remember
 
 
At SpeculatingStocks You Can Discover Stocks, Post Anonymously, and React to Posts. Login is Optional.
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap

84.49B7.91B479.47M2.87B1.32B19.04M928.71M17.72M39.7M92.89B1.04B754.33M1.66B7.93M20.47M23.2M340.3M156.51M472.4M494.12M3.41M9.59M168.19B543.86M360.11B193.81B50.16B112.8M3.03B27.42M391.15M186.82M195.54B141.07M71.74B10.72B10.47M12.63B27.64B807.73M117.27M62.41M


Recent Fighting Cancer Posts (Pulses)




08/22/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/21/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/18/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/17/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/16/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/08/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/07/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/04/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/03/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/02/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



08/01/2017: $BMY Bristol-Myers announced that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and... -- Go to this Pulse Post



07/31/2017: $BMY $CLVS Clovis Oncology to collaborate with Bristol-Myers to evaluate the combination of Opdivo and Rubraca in pivotal phase 3 clinical trials in Advanced ovarian cancer and Advanced triple-negative breast cancers. -- Go to this Pulse Post



07/27/2017: $ICAD iCAD will present clinical data supporting use of the Xoft Axxent Electronic Brachytherapy System for the treatment of endometrial cancer at the American Association of Physicists in Medicine Annual Meeting. -- Go to this Pulse Post



07/27/2017: $SNGX Soligenix has opened patient enrollment for its Phase 3 placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. -- Go to this Pulse Post



07/27/2017: $MRK $AZN AstraZeneca and Merck form strategic oncology collaboration. -- Go to this Pulse Post



07/25/2017: $RHHBY Roche Hldg has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with the Novartis drug ZYKADIA. -- Go to this Pulse Post



07/25/2017: $GALT Galectin Therapeutics received NOA for a US patent that provided intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs. -- Go to this Pulse Post



07/25/2017: $VSTM Verastem announced findings from studies evaluating focal adhesion kinase inhibition in preclinical models of pancreatic and breast cancer with the publication of two papers in the peer-reviewed journals, PLoS One and Oncotarget. -- Go to this Pulse Post



07/25/2017: $LLY Eli Lilly beat by $0.06, beat on revenue; raised FY17, in-line; announced new oncology strategy. -- Go to this Pulse Post



07/24/2017: $OCX OncoCyte 'has successfully completed the Analytical Validation study of its liquid biopsy lung cancer diagnostic test'; results consistent w/ the data reported in May at the American Thoracic Society 2017 International Conference. -- Go to this Pulse Post



07/20/2017: $ARAY Accuray announced publication of a study on intensity-modulated radiation therapy using the TomoTherapy System for patients with head and neck cancer in the International Journal of Radiation Oncology - Biology - Physics. -- Go to this Pulse Post



07/19/2017: $VNRX VolitionRx to host call tomorrow July 20 at 8:30am ET regarding 13,500 subject colorectal cancer screening trial with the Early Detection Research Network of the US National Cancer Institute. -- Go to this Pulse Post



07/19/2017: $ICAD iCAD announced publication of results of a non-melanoma skin cancer study w/ its Xoft Axxent Electronic Brachytherapy System or Mohs micrographic surgery showed that rates of recurrence of cancer were virtually identical. -- Go to this Pulse Post



07/17/2017: $PBYI Puma Biotech confirmed FDA approval for NERLYNX (neratinib) in early stage HER2-overexpressed/amplified breast cancer (halted - will resume trading 17:55 ET. -- Go to this Pulse Post



07/17/2017: $FPRX Five Prime Therapeutics initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody, in patients with advanced gastric and gastroesophageal cancer in Japan. -- Go to this Pulse Post



07/10/2017: $IMMU Immunomedics reported the publication in two prominent cancer journals of phase II clinical trial results with sacituzumab govitecan in a total of 104 patients with lung cancer, including advanced small-cell lung cancer and non-small-cell lung cancer patients who relapsed after, or were... -- Go to this Pulse Post



07/06/2017: $PBYI Puma Biotech completed patient enrollment in Ph III NALA trial of PB272 in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments in the setting of metastatic disease. -- Go to this Pulse Post